produit
Somny Z
![]() |
THE SOMNY-Z SOLUTION
INSOMNIACS... READY... READY... SLEEP!!! Oh no! Not another sleepless night! ... As usual, I didn’t sleep last night! I’m half asleep and I can’t think right…Do you recognize yourself in these simple sentences? However, you don’t have to undergo this recurring nightmare anymore! Being deprived of sleep is a nasty annoyance. For many years, this has been used as a cheap means of psychological torture.You’re out of breath?
|
contenu avec onglet
Suffering from insomnia is like going through a living hell. Insomniacs’ world seems to be a recurrent nightmare. Nights are endless and days elapse in a state of torpor. Somny Z brings a fast relief, without addiction and attenuates the symptoms associated with the lack of sleep: stress, anxiety, etc. Our formulation regularizes the mechanisms implied in the correct function of the circadian rhythm (sleep/awakening period).
Somny Z may help fight sleep disorders.Principale use
- Relaxation;
- Stress and anxiety relief;
- Sleep-inducing;
- Restful sleep without feelings of fatigue in the morning;
- Regulation of circadian rhythm: sleep-awakening cycles;
- Long-term increase in quality of sleep;
- Memory improvement by sustaining deep sleep.
Secondary Use
- Sleep disturbances;
- Chronic or transitory insomnia;
- Accumulated fatigue.
Standardization
| Plant / Ingredient | Standardization | Quantity of dried plant per 7,5 ml |
| Rice germ | GABA 40 % | 1000 mg (germs) |
| Valerian | Valerique acid 0,6 % | 600 mg (roots) |
| Griffonia | 5-HTP 5 % | 575 mg (seeds) |
| Hot | Flavonoids 1 % | 300 mg (cones) |
| Yuzu | Limonoids 0,2 % | 50 mg (seeds) |
| Inositol | S/O | 50 mg |
Pharmacologics activity
Naturel products and plants in this formulation are traditionnaly used for the following effects:VALERIAN (Valeriana officinalis)
Origin : Canada- Hypnotic (inducer of sleepl) ;
- Sedative and antidepressant.
GRIFFONIA (Griffonia simplicifolia)
Origin : Africa- Provide 5HTP in the body;
- Stimulate the production of serotonin;
- Control the activities of the pituitary gland;
- Prevent the harmful effects of cortisol.
HOP (Humulus lupulus )
Origin : Europa- Relaxant, hypnotic and sedative;
- Support digestion.
RICE GERM (Oryza sativa)
Origin : Asia- Supplies GABA to the body, allowing neurotransmitter to permit relaxation;
- Inhibiting role in the apparition mechanism of stress;
- Psychic and physical tranquillizer;
- Repair agent for the quality of sleep.
INOSITOL
- Anxiolytic, antidepressant et sedative.
YUZU (Citrus junos)
Origin : Japan- Stimulate memory and support concentration.
- Mild relaxant.
Somny Z may be used in different ways:
- Prolonged use (chronic insomnia): Take 1½ teaspoon (7,5 ml) at least 1 hour before bedtime during 1 month. Progressively reduce dosage before ending the treatment.
- Occasional use (transitory insomnia): About one hour before bedtime, take 1½ teaspoon (7,5ml) (with a small amount of juice) and keep under the tongue for a minimum of 30 to 60 seconds, then swallow. Take 1½ teaspoon more (same manner) just before bedtime.
When: Take at least 20 minutes or 1 hour before bedtime.
How: Shake the bottle and mix with juice.
*Refrigerate after opening.
SPEED OF EFFECT
- It is advised to take Somny Z from 15 to 60 minutes before bedtime, only one dose is often sufficient. Most people will see an improvement of sleep quality in 2 to 3 days;
- Average time to obtain relief from insomnia, i.e. fall asleep more quickly and be able to sleep a greater number of hours without waking up, will be from about 2 to 7 days.
Somny Z is given to those who:
- Suffer from chronic or transitory insomnia;
- Want to decrease chronic stress and accumulated tiredness;
- Wish to regulate the mechanism implied in the good function of the sleep-awake circadian rhythm;
- Wish to increase their quality of sleep in the long term;
- Suffer from stress and anxiety;
- Wish to sleep restfully without feeling tired when the alarm clock hits;
- Wish to improve memory by favoring deep sleep.
Synergic Action
The components of Somny Z act in complete synergy to regulate the mechanisms in good circadian rhythm sleep-awakening patterns.The plants in our formulation have sedative and relaxing effects on the nervous system:
- Valerian: two categories of its components were proposed to be the primary sources of the sedative effects of valerian. The first category comprises the principal components of its volatile oils, including valeric acid and its derivatives, which have shown their sedative properties in animals. The second category comprise of iridoids, including valeprotriates. The latter and their derivatives act in vivo like sedatives, but are unstable and break up during storage or in an aqueous environment thus making their activity difficult to evaluate.
- Hop: In ethnobotany, hops are recognized for their soft sedative properties. Volatile oils, humulene, β-caryophyllene and valeric acid, etc, of hops are responsible for the hypnotic and sedative action. The majority of the medicinal plant preparations to counter insomnia, mix hop with other more effective sedative plants such as valerian to potentate their effect. It is a good combination because hops have the capacity to soften the effects of valerian, in order to prevent addiction to it;
- Inositol: Studies have showed that strong amounts of inositol can be beneficial in the treatment of depression, anxiety disorders, without the side effects of prescription drugs;
- Yuzu: More recent studies in human have showed that this plant can act by calming the nervous system. Its impact is visible by encephalogram via the alpha waves which are waves of relief in the brain. This property has an impact on the capacity of concentration and the maintenance of mental serenity.
- GABA: The modulating effects of GABA’s action, inductor of sleep: Rice germs are a direct source of GABA. Valerian may cause sedation because of the quantity of GABA it contains;
- Natural serotonin precursor is in charge of the awake-sleep mechanism, i.e. the internal clock which decides when and how it is necessary to sleep and when to wake up.
Clinical studies prove that 5-HTP is useful in the treatment of sleep disorders other than insomnia. It increases REM sleep significantly, specifically by approximately 25%, whereas simultaneously, it increases paradoxical sleep of stages 3 and 4, without increasing the total sleep period. 5-HTP shortens the time in stages 1 and 2 of sleep, which are the least important stages of the cycle. The more the amount is important, the more time will lengthen in REM. By shifting the balance of the sleep cycle, the treatment will become restful and regenerating. Instead of feeling tired and dissatisfied, people who use this natural product feel impassioned, quite rested and ready to take up the daily challenges.
- Other effects on active processes, especially during sleep:
Inositol plays an important role in the health of cellular membranes and the intracellular transport, of which the calcium transport; particularly in specialized cells of the brain and spinal cord, which maintain the vitality of the central nervous system. Another role of inositol in lecithin formation, is that of the metabolism of fats and cholesterol, which facilitates the transformation of fats into energy and glucose which are the essential nourishment for the brain mechanism; a very active process during sleep;
Yuzu acts on the peripheral blood circulation level, by increasing blood flow to the brain. It also has an important cellular regenerative effect in the aging process.
Q. Can Somny-Z cause addiction like the majority of other products that fight insomnia?
A. Absolutely not. Because there are many molecules that function synergistically, the body and brain will not adapt to this product. In addition, after a few weeks of use, the body relearns to produce good amounts of neurotransmitters, therefore decreasing the accumulated stress. The majority of people may stop the use of Somny-Z without having any problems involving sleep.
Q. Can sleep be affected by menopause?
A. Women complain more than men of fatigue and other difficulties connected to lack of sleep. These complaints are more prevalent among women who are over 40 years old. However, objective measurements in laboratory studies of sleep-awake cycles showed a different response: Sleep in men seems to weaken before that of women. Between 47 and 64% of menopausal women had difficulty sleeping and more than half of them felt tired. In addition, lack of sleep and tiredness may exacerbate changes of mood among many menopausal women.
Q. Why do the elderly have trouble sleeping?
A. Between 20% and 37% of the elderly complain about sleeping problems and feel less alert as well as vigilant during the day. Objective recordings in the laboratory of sleep-awake cycles showed that there was a difference between the elderly and younger people. The elderly sleeps earlier at night and awakes earlier in the morning, experiences a shorter duration of stages 3 and 4 deep sleep, and an increase in stages 1 and 2 of light sleep. Their hours of sleep are shorter and they are awoken more frequently, especially during the second half of the night. This “fragility” of sleep may explain why so many elderly people complain of somnolence during the day and tends to take more naps than younger people. Contrary to belief, changes of sleep start well before the age of 60 years old. It is a part of adult life that ones begin with sleeping less. It is indeed from the middle of adult life that we start with less better sleep.
Immediate benefits:
- Relaxation;
- Relief of stress and accumulated tiredness during the day;
- Helps to fall asleep and sleep throughout the night without feeling tired early in the morning.
Long-term effectiveness:
- Regulation of circadian rhythm (awake-sleep);
- Abolition of chronic stress;
- Long term increase in the quality of sleep;
- Increase in the capacity to concentrate;
- Improvement of the memorization by supporting deep sleep.
Einat H, Karbovski H, Korik J, Tsalah D, Belmaker RH, Inositol reduces depressive-like behaviors in two different animal models of depression, Psychopharmacology (Berl) 1999 May;144(2):158-62.
Chrubasik S & al Treatment low back pain exacerbations with willow bark extract: a randomized double-blind study.,Am J Med. 2000 Jul;109(1):9-14. & Meyer-Buchtela, 1999; Wichtl, 1989; Wichtl and Bisset, 1994.
Andreatini R, Leite J. Effect of valepotriates on the behavior of rats in the elevated plus-maze during diazepam withdrawal. Eur J Pharmacol. 1994;260:233–235.
Balderer G, Borbely AA. Effect of valerian on human sleep. Psychopharmacol. 1985;87:406–409.
Diefenbach K, et al. Valerian effects on microstructure of sleep in insomniacs. (2nd Congress of the European Assoc. for Clinical Pharmacology and Therapeutics, Berlin, Germany, Sept. 17-20.) Eur J Clin Pharmacol. 1997;52 (suppl):A169.
D'Arcy PF. Adverse reactions and interactions with herbal medicines. Part 2—Drug interactions. Adverse Drug React Toxicol Rev. 1993;12(3):147–162.
Hendriks H, Bos R, Woerdenbag HJ, et al. Central nervous depressant activity of valerenic acid in the mouse. Planta Med. 1985;1:28–31.
Hiller K-O, Zetler G. Neuropharmacological studies on ethanol extracts of Valeriana officinalis L.: behavioral and anticonvulsant properties. Phyto Ther. 1996;10:145–151.
Leathwood PD. Aqueous extract of valerian root (Valeriana officinalis L.) improves sleep quality in man. Pharmacol Biochem Behav. 1982;17:65–71.
Leuschner J, Muller J, Rudmann M. Characterization of the central nervous depressant activity of a commercially available valerian root extract. Arzneim-Forsch. 1993;43:638–641.
Lindahl O, Lindwall L. Double-blind study of a valerian preparation. Pharmacol Biochem Behav. 1989;32:1065–1066.
Mennini T, Bernasconi P. In vitro study on the interaction of extracts and pure compounds from Valeriana officianalis roots with GABA, benzodiazepine, and barbiturate receptors. Fitoterapia. 1993;64:291–300.
Santos MS. Synaptosomal GABA release as influenced by valerian root extract—involvement of the GABA carrier. Arch Int Pharmacodyn Ther. 1994; 327:220–231.
Seifert T. Therapeutic effects of valerian in nervous disorders: a field study. Therapeutikon. 1988;2(94).
Schultz H, Stolz C, Muller J. The effect of valerian extract on sleep polygraph in poor sleepers: a pilot study. Pharmacopsychiatry. 1994;27:147–151.
Balderer G, Borbely AA. Effect of valerian on human sleep. Psychopharmacology (Berl). 1985;87(4):406-9.
Cauffield JS, Forbes HJ. Dietary suppléments used in the treatment of depression, anxiety, and sleep disorders. Lippincotts Prim Care Pract. 1999 May-Jun;3(3):290-304.
Cerrato PL. Natural tranquilizers? RN. 1998 Dec;61(12):61-2.
Donath F, Quispe S, Diefenbach K, Maurer A, Fietze I, Roots I. Critical evaluation of the effect of valerian extract on sleep structure and sleep quality. Pharmacopsychiatry. 2000 Mar;33(2):47-53.
Dorn M. Efficacy and tolerability of Baldrian versus oxazepam in non-organic and non-psychiatric insomniacs: a randomised, double-blind, clinical, comparative study. Forsch Komplementarmed Klass Naturheilkd. 2000 Apr;7(2):79-84.
Houghton PJ. The scientific basis for the reputed activity of Valerian. J Pharm Pharmacol. 1999 May;51(5):505-12.
Kohnen R, Oswald WD. The effects of valerian, propranolol, and their combination on activation, performance, and mood of healthy volunteers under social stress conditions. Pharmacopsychiatry. 1988 Nov;21(6):447-8.
Thierolf H. Contribution on the treatment of nervous manifestations. Landarzt. 1964 Sep 10;40(25):1086-7.
Brinker Francis, Herb contraindications and drug interactions, third edition, Sandy, OR: Electic medical publications; 2001.
Brown DJ, Herbal Prescriptions for Better Health, Rocklin, CA: Prima Publishing; 1996; 279.
Chevallier, A, The Encyclopedia of Medicinal Plants, London, UK: Dorling Kindersley; 1996.
Eagon CL, Elm MS, Eagon PK, Estrogenicity of traditional Chinese and Western herbal remedies: Proc Annu Meet Am Assoc Cancer Res; 1996; 37:A1937 [abstract].
European Scientific Cooperative on Phytotherpy (ESCOP), Monographs on the Medicinal Uses of Plant Drugs, Exeter, UK: ESCOP; 1999.
Fleming T, PDR for Herbal Medicines, Physicians’ Desk Reference, second edition, Montvale, NJ: Thomson Medical Economics; 2000; 400-401.
Newmark FM, Hops allergy and terpene sensitivity: An occupational disease: Ann Allergy; 1978; 41:311-312.
USDA, ARS, National Genetic Resources Program, Germoplasm Resources Information Network (GRIN). [Internet] 1999 [cited September 5, 2004] Available from http://www.ars-grin.gov/cgi-bin/npgs/html/tax_search.pl
Weiss RF, Herbal Medicine, Gothenburg, Sweden: Ab Arcanum; 1988; 285-6.
Wichtl M, Herbal Drugs and Phytopharmaceuticals, Boca Raton, FL: CRC Press; 1994; 305-8.
Goodman and Gilman’s, the pharmacological basic of therapeutics, seventh edition, 1985, Amino-acid P.247-250; 487.
Therapeutic Research Faculty (Ed). Rice bran, Natural Medicines Comprehensive Database. www.naturaldatabase.com
Huke R.E., Huke E.H. Rice: Then and Now. International Rice Research Institute, 1990. Riceweb.org www.riceweb.org
International Rice Research Institute. Riceweb: A compendium of facts and figures from the world of rice. Riceweb.org. www.riceweb.org
Levine J, Barak Y, Gonzalves M, et al. Double-blind, controlled trial of inositol treatment of depression. Am J Psychiatry 1995;152:792–4.
http://www.pdrhealth.com/drug_info/nmdrugprofiles/nutsupdrugs/myo_0145.shtml
Levine J, Barak Y, Kofman O, Belmaker RH. Follow-up and relapse analysis of an inositol study of depression. Isr J Psychiatry Relat Sci 1995;32:14–21.
Benjamin J, Levine J, Fux M, et al. Double-blind, placebo-controlled, crossover trial of inositol treatment for panic disorder. Am J Psychiatry 1995;152:1084–6.
Fox M, Levine J, Aviv A, Belmaker RH. Inositol treatment of obsessive-compulsive disorder. Am J Psychiatry 1996;153:1219–21.
Colodny L, Hoffman RL. Inositol—Clinical applications for exogenous use. Altern Med Rev 1998;3:432–47.
The Natural Pharmacist (Ed). Natural Products Encyclopedia, Herbs & Suppléments - 5-HTP, ConsumerLab.com. [Consulté le 18 février 2003]. www.consumerlab.com
Therapeutic Research Faculty (Ed). 5-HTP, Natural Medicines Comprehensive Database. [Consulté le 18 février 2003]. www.naturaldatabase.com
U. S. Food and Drug Administration. Background on L-tryptophan and 5-hydroxy L-tryptophan and the eosinophilia myalgia syndrome. États-Unis, 2001. [Consulté le 18 février 2003].
http://vm.cfsan.fda.gov Eleanor Noss Whitney, Corinne Balog Cataldo, Sharon Rady Rolfes. Understanding normal and clinical nutrition, 6th Edition, États-Unis, 2002.
http://ift.confex.com/ift/2004/techprogram/paper_22641.htm, Effect of antioxidant flavanone, naringenin, from Citrus junos on neuroprotection
Hume, H.H. 1957. Citrus fruits. The Macmillan Co. New York. pp. 390 – 395.
Chrubasik S & al Treatment low back pain exacerbations with willow bark extract: a randomized double-blind study.,Am J Med. 2000 Jul;109(1):9-14. & Meyer-Buchtela, 1999; Wichtl, 1989; Wichtl and Bisset, 1994.
Andreatini R, Leite J. Effect of valepotriates on the behavior of rats in the elevated plus-maze during diazepam withdrawal. Eur J Pharmacol. 1994;260:233–235.
Balderer G, Borbely AA. Effect of valerian on human sleep. Psychopharmacol. 1985;87:406–409.
Diefenbach K, et al. Valerian effects on microstructure of sleep in insomniacs. (2nd Congress of the European Assoc. for Clinical Pharmacology and Therapeutics, Berlin, Germany, Sept. 17-20.) Eur J Clin Pharmacol. 1997;52 (suppl):A169.
D'Arcy PF. Adverse reactions and interactions with herbal medicines. Part 2—Drug interactions. Adverse Drug React Toxicol Rev. 1993;12(3):147–162.
Hendriks H, Bos R, Woerdenbag HJ, et al. Central nervous depressant activity of valerenic acid in the mouse. Planta Med. 1985;1:28–31.
Hiller K-O, Zetler G. Neuropharmacological studies on ethanol extracts of Valeriana officinalis L.: behavioral and anticonvulsant properties. Phyto Ther. 1996;10:145–151.
Leathwood PD. Aqueous extract of valerian root (Valeriana officinalis L.) improves sleep quality in man. Pharmacol Biochem Behav. 1982;17:65–71.
Leuschner J, Muller J, Rudmann M. Characterization of the central nervous depressant activity of a commercially available valerian root extract. Arzneim-Forsch. 1993;43:638–641.
Lindahl O, Lindwall L. Double-blind study of a valerian preparation. Pharmacol Biochem Behav. 1989;32:1065–1066.
Mennini T, Bernasconi P. In vitro study on the interaction of extracts and pure compounds from Valeriana officianalis roots with GABA, benzodiazepine, and barbiturate receptors. Fitoterapia. 1993;64:291–300.
Santos MS. Synaptosomal GABA release as influenced by valerian root extract—involvement of the GABA carrier. Arch Int Pharmacodyn Ther. 1994; 327:220–231.
Seifert T. Therapeutic effects of valerian in nervous disorders: a field study. Therapeutikon. 1988;2(94).
Schultz H, Stolz C, Muller J. The effect of valerian extract on sleep polygraph in poor sleepers: a pilot study. Pharmacopsychiatry. 1994;27:147–151.
Balderer G, Borbely AA. Effect of valerian on human sleep. Psychopharmacology (Berl). 1985;87(4):406-9.
Cauffield JS, Forbes HJ. Dietary suppléments used in the treatment of depression, anxiety, and sleep disorders. Lippincotts Prim Care Pract. 1999 May-Jun;3(3):290-304.
Cerrato PL. Natural tranquilizers? RN. 1998 Dec;61(12):61-2.
Donath F, Quispe S, Diefenbach K, Maurer A, Fietze I, Roots I. Critical evaluation of the effect of valerian extract on sleep structure and sleep quality. Pharmacopsychiatry. 2000 Mar;33(2):47-53.
Dorn M. Efficacy and tolerability of Baldrian versus oxazepam in non-organic and non-psychiatric insomniacs: a randomised, double-blind, clinical, comparative study. Forsch Komplementarmed Klass Naturheilkd. 2000 Apr;7(2):79-84.
Houghton PJ. The scientific basis for the reputed activity of Valerian. J Pharm Pharmacol. 1999 May;51(5):505-12.
Kohnen R, Oswald WD. The effects of valerian, propranolol, and their combination on activation, performance, and mood of healthy volunteers under social stress conditions. Pharmacopsychiatry. 1988 Nov;21(6):447-8.
Thierolf H. Contribution on the treatment of nervous manifestations. Landarzt. 1964 Sep 10;40(25):1086-7.
Brinker Francis, Herb contraindications and drug interactions, third edition, Sandy, OR: Electic medical publications; 2001.
Brown DJ, Herbal Prescriptions for Better Health, Rocklin, CA: Prima Publishing; 1996; 279.
Chevallier, A, The Encyclopedia of Medicinal Plants, London, UK: Dorling Kindersley; 1996.
Eagon CL, Elm MS, Eagon PK, Estrogenicity of traditional Chinese and Western herbal remedies: Proc Annu Meet Am Assoc Cancer Res; 1996; 37:A1937 [abstract].
European Scientific Cooperative on Phytotherpy (ESCOP), Monographs on the Medicinal Uses of Plant Drugs, Exeter, UK: ESCOP; 1999.
Fleming T, PDR for Herbal Medicines, Physicians’ Desk Reference, second edition, Montvale, NJ: Thomson Medical Economics; 2000; 400-401.
Newmark FM, Hops allergy and terpene sensitivity: An occupational disease: Ann Allergy; 1978; 41:311-312.
USDA, ARS, National Genetic Resources Program, Germoplasm Resources Information Network (GRIN). [Internet] 1999 [cited September 5, 2004] Available from http://www.ars-grin.gov/cgi-bin/npgs/html/tax_search.pl
Weiss RF, Herbal Medicine, Gothenburg, Sweden: Ab Arcanum; 1988; 285-6.
Wichtl M, Herbal Drugs and Phytopharmaceuticals, Boca Raton, FL: CRC Press; 1994; 305-8.
Goodman and Gilman’s, the pharmacological basic of therapeutics, seventh edition, 1985, Amino-acid P.247-250; 487.
Therapeutic Research Faculty (Ed). Rice bran, Natural Medicines Comprehensive Database. www.naturaldatabase.com
Huke R.E., Huke E.H. Rice: Then and Now. International Rice Research Institute, 1990. Riceweb.org www.riceweb.org
International Rice Research Institute. Riceweb: A compendium of facts and figures from the world of rice. Riceweb.org. www.riceweb.org
Levine J, Barak Y, Gonzalves M, et al. Double-blind, controlled trial of inositol treatment of depression. Am J Psychiatry 1995;152:792–4.
http://www.pdrhealth.com/drug_info/nmdrugprofiles/nutsupdrugs/myo_0145.shtml
Levine J, Barak Y, Kofman O, Belmaker RH. Follow-up and relapse analysis of an inositol study of depression. Isr J Psychiatry Relat Sci 1995;32:14–21.
Benjamin J, Levine J, Fux M, et al. Double-blind, placebo-controlled, crossover trial of inositol treatment for panic disorder. Am J Psychiatry 1995;152:1084–6.
Fox M, Levine J, Aviv A, Belmaker RH. Inositol treatment of obsessive-compulsive disorder. Am J Psychiatry 1996;153:1219–21.
Colodny L, Hoffman RL. Inositol—Clinical applications for exogenous use. Altern Med Rev 1998;3:432–47.
The Natural Pharmacist (Ed). Natural Products Encyclopedia, Herbs & Suppléments - 5-HTP, ConsumerLab.com. [Consulté le 18 février 2003]. www.consumerlab.com
Therapeutic Research Faculty (Ed). 5-HTP, Natural Medicines Comprehensive Database. [Consulté le 18 février 2003]. www.naturaldatabase.com
U. S. Food and Drug Administration. Background on L-tryptophan and 5-hydroxy L-tryptophan and the eosinophilia myalgia syndrome. États-Unis, 2001. [Consulté le 18 février 2003].
http://vm.cfsan.fda.gov Eleanor Noss Whitney, Corinne Balog Cataldo, Sharon Rady Rolfes. Understanding normal and clinical nutrition, 6th Edition, États-Unis, 2002.
http://ift.confex.com/ift/2004/techprogram/paper_22641.htm, Effect of antioxidant flavanone, naringenin, from Citrus junos on neuroprotection
Hume, H.H. 1957. Citrus fruits. The Macmillan Co. New York. pp. 390 – 395.
Here are combinations of products suggested for individuals suffering from the following problems:
- Stressful living conditions: Relaximum helps to fight tension and symptoms of stress thus helping to provide a much more peaceful sleep and rest. It is a remarkable adjunct therapy to Somny-Z.
- For women: Sleep disturbances and anxiety: when a woman suffers from symptoms associated with menopause, her sleep, mood, etc. are disturbed. Flash-Meno assists by bringing a more refreshing sleep by reducing these disadvantages.
Reviews
Find a Product
|
|
|
Use with
|
|


